Expertise in
5
conditions

Gertjan J. Wolbink

Amsterdam, NH, NL 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
5
conditions
Amsterdam, NH, NL 

Overview

Gertjan Wolbink practices in Amsterdam, Netherlands. Wolbink is highly rated in 5 conditions, according to our data. Their top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Ankylosing Spondylitis, and Psoriasis.

Their clinical research consists of co-authoring 107 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Amsterdam, NH 1066CX, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Concentration-guided Dose Reduction Versus Standard Dosing in Tocilizumab-treated Rheumatoid Arthritis Patients: a Randomised, Multicenter, Non-inferiority Trial (TODORA)
Concentration-guided Dose Reduction Versus Standard Dosing in Tocilizumab-treated Rheumatoid Arthritis Patients: a Randomised, Multicenter, Non-inferiority Trial (TODORA)
Enrollment Status: Recruiting
Publish Date: April 18, 2024
Intervention Type: Drug
Study Drug: Tocilizumab
Study Phase: Phase 4
Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity: a Single Blind, Non-inferiority, Randomised Clinical Trial
Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity: a Single Blind, Non-inferiority, Randomised Clinical Trial
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Other, Drug
Study Drug: Adalimumab
Study Phase: Phase 4
View 1 Less Clinical Trial

107 Total Publications

The Association Between Serum Drug Concentration and a Flare in Rheumatoid Arthritis Patients Tapering TNF Inhibitors.
The Association Between Serum Drug Concentration and a Flare in Rheumatoid Arthritis Patients Tapering TNF Inhibitors.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: August 11, 2025

Frequently Asked Questions about Gertjan J. Wolbink

Is Gertjan J. Wolbink a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Gertjan J. Wolbink is classified as an Distinguished expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Gertjan J. Wolbink participate in research or clinical trials?

Yes. Gertjan J. Wolbink has published 107 articles and abstracts on conditions like Rheumatoid Arthritis (RA). You can view a list of Gertjan J. Wolbink's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wolbink's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile